Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 8/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21103703 | 1.00 | TDP1 (0.32) | TDP1GLP1RMEN1KMT2ACA1 | |
| SCHEMBL26081443 | 0.93 | TDP1 (0.32) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL18501606 | 0.90 | TDP1 (0.36) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL25671082 | 0.90 | TDP1 (0.36) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL21104000 | 0.82 | CAPN1 (0.33) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL24130897 | 0.74 | TDP1 (0.35) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL26229075 | 0.74 | KMT2A (0.38) | TDP1MEN1KMT2AGAACAPN1 | |
| SCHEMBL26229151 | 0.72 | TSHR (0.41) | MEN1KMT2A | |
| SCHEMBL25671162 | 0.72 | TDP1 (0.40) | TDP1MEN1KMT2AGAA | |
| SCHEMBL25671080 | 0.72 | TDP1 (0.40) | TDP1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753638-B2 | Conjugated oligonucleotides | UNIVERSITY OF MASSACHUSETTS (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753638-B2 | Conjugated oligonucleotides | DCLRE1B, DCLRE1A, TNNC1 | TDP1 400/4885GLP1R 4059/4885MEN1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.